



MicroPort Scientific Completes Acquisition of Wright Medical's OrthoRecon Business

SHANGHAI – January 10, 2014 – MicroPort Scientific Corporation (HK: 0853) today confirms the closing of the transaction to acquire the OrthoRecon business from Wright Medical Group, Inc. (NASDAQ: WMGI).

MicroPort Scientific and Sorin Group Sign Joint Venture Agreement for Cardiac Rhythm Management Business in China

Shanghai, China and Milan, Italy, January 9, 2014 – MicroPort Scientific Corporation (HK: 00853) and Sorin Group (Reuters Code: SORN.MI), announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management (CRM) devices in China.

Acquisition of Drug Eluting Stent Assets and License of Intellectual Property from Cordis

SHANGHAI, China – January 20, 2014 – MicroPort Scientific Corporation (HK: 0853) and Johnson & Johnson, Inc. (NYSE: JNJ) has entered into a definitive agreement under which MicroPort Scientific Corporation acquires certain assets from Cordis, which include formal Conor Medsystems and NEVO DES related patents and other intellectual property.

Firehawk® Rapamycin Target Eluting Coronary Stent was approved by CFDA

Shanghai, China – 28 January 2014 - Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®") has been approved for market launch by the China Food and Drug Administration ("CFDA").

Shanghai MicroPort EP MedTech Announces First Case of the Clinical Trial Of FlashPoint™ Renal Artery RF Ablation System

On 12 December 2013, Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that it has completed the first case of the clinical trial of FlashPoint™.

Appointment of Non-executive Director and Member of Nomination Committee

The 4th of fiscal year 2013 Board meeting was held on 9 December 2013. The Board of the Company announces the following changes to the Board and nomination committee with effect from 9 December 2013.



Contents

MicroPort Scientific Completes Acquisition of Wright Medical's OrthoRecon Business

MicroPort Scientific and Sorin Group Sign Joint Venture Agreement for Cardiac Rhythm Management Business in China

Acquisition of Drug Eluting Stent Assets and License of Intellectual Property from Cordis

Firehawk® Rapamycin Target Eluting Coronary Stent was approved by CFDA

Shanghai MicroPort EP MedTech Announces First Case of the Clinical Trial Of FlashPoint™ Renal Artery RF Ablation System Committee

Appointment of Non-executive Director and Member of Nomination Committee

MicroPort Scientific Completes Acquisition of Wright Medical's OrthoRecon Business



SHANGHAI – January 10, 2014 – MicroPort Scientific Corporation (HK: 0853) today confirms the closing of the transaction to acquire the OrthoRecon business from Wright Medical Group, Inc. (NASDAQ: WMGI). The acquisition was completed on January 9, 2014 and establishes MicroPort Orthopedics as the sixth largest multinational hip and knee orthopedic reconstruction business.

"MicroPort is deeply committed to the success of the orthopedics business and will continue to provide the focus and investment to enable it to reach its full potential while delivering on our mandate which is to build our portfolio of high quality, innovative and live-improving products," said Dr. Zhaohua Chang, Founder, Chairman and Chief Executive Officer of MicroPort Scientific.

The acquisition establishes the Arlington, TN facility as the global headquarters for MicroPort's orthopedics business, which includes U.S. manufacturing, global infrastructure and logistics, operations in the top four global orthopedic markets as well as established hip and knee franchise brands. With over 700 employees globally, MicroPort Orthopedics is MicroPort's largest division.

Ted Davis, Chief Executive Officer of MicroPort Orthopedics, stated, "This is an exciting transaction for

the MicroPort Orthopedics team, our partners, our customers, our patients and the communities we operate in. It's an opportunity for us to build upon 60 years of innovative leadership in the hip and knee industry, to expand our orthopedics business segment and establish MicroPort as a worldwide provider of effective and affordable orthopedics management solutions."

"MicroPort's commitment to growth and research & development is the engine that drives our market leadership position in the cardiovascular market in China today," said Jonathan Chen, VP International Business & Investor Relations, MicroPort Scientific. "This philosophy extends to MicroPort Orthopedics as well as shareholders, patients and partners who can expect that our orthopedics business will be just as innovative."

Back to Top

MicroPort Scientific and Sorin Group Sign Joint Venture Agreement for Cardiac Rhythm Management Business in China

Shanghai, China and Milan, Italy, January 9, 2014 – MicroPort Scientific Corporation (HK: 0853) and Sorin Group (Reuters Code: SORN.MI), announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management (CRM) devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest. In accordance with the agreement, MicroPort and Sorin shall make initial capital contributions of, respectively, RMB62,220,000 (USD10.2 million) and of RMB59,780,000 (USD9.8 million) in cash in the joint-venture company.

The new venture, which will be named MicroPort Sorin CRM (Shanghai) Co. Ltd., will be located in Shanghai

and is scheduled to start operations in the first half of 2014. Under the agreement, the two companies will collaborate, through the joint venture, on the import, sale and service of Sorin's CRM devices in Greater China and, in parallel, in accelerating the development of locally manufactured CRM products for the Chinese market. Significant engineering and development resources from both parties will transition to the joint venture immediately.

This new venture brings together two respected industry leaders, leveraging complementary strengths: MicroPort's unparalleled Chinese market coverage and strong national reputation and Sorin's 40 years' experience in the development and manufacture of high quality and innovative CRM devices. MicroPort and Sorin believe that the joint venture will be well positioned to quickly penetrate the growing CRM market in China. According to industry research, the Chinese CRM market, still underpenetrated, is estimated to be approximately USD500 million, growing approximately 10% per year in the next 5 years.

"This agreement represents a key milestone in MicroPort's strategy, enabling us to enter in the rapidly growing Chinese CRM market and expanding our high-end medical device product portfolio. We recognize Sorin as an innovative player in the CRM field and we are looking forward to supporting the commercialization of Sorin's devices and ultimately realizing our goal to develop locally manufactured devices which are specifically designed for China and fit the needs of the growing demand in our country", commented Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort Scientific Corporation.

"This is an important milestone in our strategy to build a local presence in China. Access to CRM therapies in China is expected to expand rapidly and the market should grow at double digit rates in the foreseeable future. Expanding our footprint in China in CRM is key

to our long-term growth strategy," said André-Michel Ballester, Chief Executive Officer of Sorin Group. "MicroPort, whose strong reputation, broad distribution network and talented management team is recognized by its customers, is the ideal CRM partner for Sorin in China."

The transaction is subject to customary closing conditions, including receipt of regulatory clearances.

Back to Top

Acquisition of Drug Eluting Stent Assets and License of Intellectual Property from Cordis

SHANGHAI, China – January 20, 2014 – MicroPort Scientific Corporation (HK: 0853) and Johnson & Johnson, Inc. (NYSE: JNJ) has entered into a definitive agreement under which MicroPort Scientific Corporation acquires certain assets from Cordis, which include formal Conor Medsystems and NEVO DES related patents and other intellectual property. In addition, MicroPort also obtains a non-exclusive license for worldwide rights to certain of Cordis' DES patents and related intellectual property.


Johnson & Johnson acquired Conor Medsystems Inc. in November 2006. Subsequently, it developed the next-generation drug-eluting stent NEVO and finished clinical studies needed for obtaining CE approval. In June 2011, Johnson & Johnson made an announcement to exit the coronary stent market.

"In coronary stent product field, Johnson & Johnson was a well-respected innovator and leader, which had developed the first Bare Metal Stent as well as the first Drug Eluting Stent in the world. J & J have accumulated comprehensive knowledge regarding product development, quality system management, clinical trial and worldwide access in the past years. Meanwhile, Johnson & Johnson has formed excellent product pipeline and intellectual property in this field,"

said Mr. Zhirong Tang, Vice President of Coronary Product Development of Shanghai MicroPort Medical (Group) Co., Ltd. "With this acquisition, MicroPort is better positioned to develop the next generation stents." Mr. Qiyi Luo, Chief Technology Officer of the Company further commented, "This transaction will further secure MicroPort's leading position in the Targeted Eluting Stent Technology and provide a reliable platform for the successful commercialization of the Firehawk, which is the innovative third generation of Drug Eluting Stent developed exclusively by MicroPort."

Back to Top

Firehawk® Rapamycin Target Eluting Coronary Stent was approved by CFDA



Shanghai, China – 28 January 2014. Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®") has been approved for market launch by the China Food and Drug Administration ("CFDA"). Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort") in-house developed, Firehawk® drug-eluting stent ("DES"), is the company's third generation coronary stent used for the treatment of coronary artery stenosis and occlusion.

Mr. Zhirong Tang, the Vice President of Coronary R&D for MicroPort, stated, the applied targeted eluting technology allows Firehawk® to achieve the same clinical efficacy as other traditional DES with only 1/3 dosage of the drug, and therefore greatly improving the safety of Firehawk® DES while maintaining its

excellent efficacy. Mr. Qiyi Luo, CTO of MicroPort stated: "Targeted Drug Eluting technology is the key milestone of DES technology's research and development. We have spent almost eight years on research and development to make Firehawk® the lowest drug dosage DES in the world. Firehawk® combines all the advantages of DES and bare metal stents. For MicroPort it represents a major leap forward, transforming our DES offering from a market follower to leader in this segment." Mr. Yimin Xu, Senior Vice President of Regulatory and Clinical Affairs of MicroPort said: "the introduction of Firehawk® is based on solid evidence-based medical data. MicroPort is the first company to conduct a large scale pre-market clinical study in accordance with <Guidance for Industry: Coronary Drug-Eluting Stents Clinical Studies>."

Firehawk® pre-marketing clinical studies consisted of three phases and 1,261 patients in total enrolled in clinical trials. This represents the largest scale premarket clinical trial of a coronary DES in China. Twenty-nine clinical centers in fourteen provinces throughout China witnessed the safety and effectiveness of Firehawk® in Target I randomized key trial, for the first time in China, Xience V (most popular DES in the United States of America and European market) was chosen for comparison with Firehawk®. The results of nine-month Angiographic follow-up, and one year clinical follow up show that Firehawk® has the same efficacy and safety as Xience V.

Dr. Runlin Gao, MD, (principal investigator for Firehawk® Target I Randomized Controlled Trial (RCT)) said, " The approval of Firehawk by CFDA, added a new therapy choice for the patients, the safety and efficacy of Firehawk were proved to be world class by the well conducted clinical trials. " and Dr. Martin B. Leon, MD, chairman of TCT, and the co-principal investigator of TARGET, had made comments during TCT 2012, "I think a device like this, with abluminal coating, biodegradable polymers staying in the grooves,

not exposed and with a low drug dose, DAPT shorten to 3 months in the future should be reasonable, MicroPort should be considered as a world leader in DES with its Firehawk technology."

In the Chinese market Firebird stents have held the leading position for nine consecutive years and we believe the launch of Firehawk® will strengthen our leading position in the field of coronary intervention. MicroPort is committed to bringing Firehawk® to the international markets and the application for CE approval is in the process.

Back to Top

Shanghai MicroPort EP MedTech Announces First Case of the Clinical Trial Of FlashPoint™ Renal Artery RF Ablation System

On 12 December 2013, Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that it has completed the first case of the clinical trial of FlashPoint™ Renal Artery RF Ablation System in which the case was performed under the affiliation with Guangxi Medical University by Professor Lang Li. FlashPoint™ is independently developed by Shanghai MicroPort EP MedTech. "This is a prospective, multicenter, randomized controlled clinical trial and the successful completion of the first clinical trial case suggests that it has formally entered into clinical research stage," said Dr. Yiyong Sun, the President of Shanghai MicroPort EP MedTech. "MicroPort EP MedTech will be further working on the development of the product and provide better options for patients with treatment-resistant hypertension."

Back to Top

Appointment of Non-executive Director and Member of Nomination Committee

The 4th of fiscal year 2013 Board meeting was held on 9 December 2013. The Board of the Company announces the following changes to the Board and nomination committee with effect from 9 December 2013:

1. Mr. Ganjin Chen has been appointed as a non-executive director and member of nomination committee of the Company; and
2. Mr. Lei Ding has resigned as a non-executive director and member of nomination committee of the Company.

Biography

Mr. Ganjin Chen, born in 1968, was appointed as the Non-executive Director of the Company on 9 December 2013. Mr. Ganjin Chen is also a director of Shanghai Medical Devices (Group) Co., Ltd, Leader City Limited and MicroPort Medical Limited (other members of the Company). Mr. Ganjin Chen is the secretary of the party committee and general manager of Shanghai Zhangjiang (Group) Co., Ltd as well as the deputy secretary of the party committee and executive deputy director of the management committee of Shanghai Zhangjiang Hi-Tech Park. Mr. Ganjin Chen graduated from Xi'an Jiaotong University with a Bachelor Degree of thermal energy & power engineering and China Europe International Business School with a Master of Business Administration.

Back to Top